We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+4.37%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$1.14B
AUM Growth
+$113M
Cap. Flow
+$131M
Cap. Flow %
11.52%
Top 10 Hldgs %
48.07%
Holding
60
New
9
Increased
13
Reduced
15
Closed
3

Top Buys

Rank Stock Value
1
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$33.5M
2
ARRY
Array Biopharma Inc
ARRY
+$24.8M
3
ACIU icon
AC Immune
ACIU
+$20.3M
4
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$16.8M
5
REPL icon
Replimune Group
REPL
+$16M

Top Sells

Rank Stock Value
1
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$11.6M
2
ARQL
Arqule Inc
ARQL
+$9.22M
3
ANAB icon
AnaptysBio
ANAB
+$7.05M
4
ONCT
Oncternal Therapeutics, Inc. Common Stock
ONCT
+$5.91M
5
FBRX icon
Forte Biosciences
FBRX
+$4.4M

Sector Composition

Rank Sector Weight
1 Healthcare 84.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARRY
1
DELISTED
Array Biopharma Inc
ARRY
$95.6M 8.4%
6,290,586
+1,618,391
+35% +$24.8M
CCXI
2
DELISTED
ChemoCentryx, Inc.
CCXI
$85.6M 7.52%
6,773,760
-260,586
-4% -$3.14M
MRUS
3
DELISTED
Merus
MRUS
$77.3M 6.79%
3,914,913
– –
CYTK icon
4
Cytokinetics
CYTK
$10.9B
$51.1M 4.49%
5,186,839
-364,051
-7% -$2.92M
FPRX
5
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$47.1M 4.14%
3,381,117
+2,251,356
+199% +$33.5M
BPMC
6
DELISTED
Blueprint Medicines
BPMC
$46.7M 4.1%
598,267
-48,544
-8% -$3.37M
INFI
7
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$41.3M 3.63%
15,232,268
– –
KURA icon
8
Kura Oncology
KURA
$826M
$35.3M 3.1%
2,015,856
-41,490
-2% -$795K
MRTX
9
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$34.1M 2.99%
723,322
-21,678
-3% -$1.21M
ARQL
10
DELISTED
Arqule Inc
ARQL
$33M 2.9%
5,827,902
-1,620,010
-22% -$9.22M
XNCR icon
11
Xencor
XNCR
$1.59B
$32.6M 2.87%
837,538
-32,107
-4% -$1.31M
PVLA
12
Palvella Therapeutics
PVLA
$2.15B
$31.4M 2.76%
70,007
+3,172
+5% +$1.38M
BLRX
13
BioLineRX
BLRX
$11.7M
$27.8M 2.44%
43,326
– –
PTGX icon
14
Protagonist Therapeutics
PTGX
$8.92B
$26.9M 2.37%
2,617,967
+1,200,000
+85% +$10.3M
IONS icon
15
Ionis Pharmaceuticals
IONS
$8.85B
$26.8M 2.36%
520,000
-50,000
-9% -$2.35M
XOMA
16
DELISTED
Xoma
XOMA
$26.4M 2.32%
1,502,800
– –
ANAB icon
17
AnaptysBio
ANAB
$1.63B
$25M 2.19%
250,265
-85,000
-25% -$7.05M
GLMD icon
18
Galmed Pharmaceuticals
GLMD
$4.95M
$23.9M 2.1%
9,786
– –
CNCE
19
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$23.6M 2.08%
1,592,138
-225,000
-12% -$3.54M
FWP
20
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$19.4M 1.7%
1,214,704
-71
-0% -$1.39K
DRNA
21
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$17.6M 1.54%
+1,152,073
New +$16.8M
CRVS icon
22
Corvus Pharmaceuticals
CRVS
$1.11B
$16.2M 1.43%
1,890,507
– –
ACIU icon
23
AC Immune
ACIU
$241M
$16.1M 1.42%
+2,017,500
New +$20.3M
IMDZ
24
DELISTED
Immune Design Corp.
IMDZ
$16.1M 1.41%
4,658,353
+500,000
+12% +$1.88M
SPRO icon
25
Spero Therapeutics
SPRO
$69.5M
$15.6M 1.37%
1,488,088
+439,130
+42% +$5.1M
1
2 3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q3 2018 Portfolio in Review

As of Q3 2018, BVF Inc held 60 positions worth $1.14B, up 11% from $1.02B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

BVF Inc deployed $131M of net new capital in Q3 2018, opening 9 new positions and adding to 13 existing holdings. Its largest new stake was AC Immune: 2,017,500 shares worth $16.1M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 84% a quarter earlier.

On the sell side, the largest reduction was Arqule Inc, an estimated $9.22M trimmed.

  • BVF Inc's largest Q3 2018 buy was AC Immune: 2,017,500 shares worth $16.1M.
  • BVF Inc added most to Five Prime Therapeutics, Inc. in Q3 2018, an estimated $33.5M increase.
  • BVF Inc's biggest Q3 2018 reduction was Arqule Inc, cutting an estimated $9.22M.
  • BVF Inc fully exited Ironwood Pharmaceuticals in Q3 2018, selling an estimated $11.6M.
  • BVF Inc's ten largest holdings make up 48% of its $1.14B portfolio in Q3 2018.
  • BVF Inc opened 9 new positions and closed 3 in Q3 2018.
  • BVF Inc's portfolio value rose 11% quarter-over-quarter to $1.14B.

Based on BVF Inc's 13F filing for Q3 2018, filed 14 Nov 2018.